APA (7th ed.) Citation

ML, A., A, J., & M, K. (2020). Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab. Drugs of today (Barcelona, Spain : 1998), 56(4), 287. https://doi.org/10.1358/dot.2020.56.4.3127026

Chicago Style (17th ed.) Citation

ML, Amaya, Jimeno A, and Kamdar M. "Polatuzumab Vedotin to Treat Relapsed or Refractory Diffuse Large B-cell Lymphoma, in Combination with Bendamustine Plus Rituximab." Drugs of Today (Barcelona, Spain : 1998) 56, no. 4 (2020): 287. https://doi.org/10.1358/dot.2020.56.4.3127026.

MLA (9th ed.) Citation

ML, Amaya, et al. "Polatuzumab Vedotin to Treat Relapsed or Refractory Diffuse Large B-cell Lymphoma, in Combination with Bendamustine Plus Rituximab." Drugs of Today (Barcelona, Spain : 1998), vol. 56, no. 4, 2020, p. 287, https://doi.org/10.1358/dot.2020.56.4.3127026.